New research indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end conventional diet and exercise plans.
Published data in a leading health publication demonstrates that while overweight people can lose about a fifth of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Individuals using such drugs need to be informed of the potential of quick rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment weight within about 18 months.
Analyzing Treatments
The research, which looked at 37 of studies involving over 9,000 of patients, contrasted the outcomes of GLP-1 agonists with other pills.
Scientists note that people who lose weight through diet and exercise usually experience a less rapid creep back—approximately 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Doctors suggest the mechanism of the drugs is key to understanding the amplified rebound.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement leads to hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Issue?
The NHS suggest the injections for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, given the high risk of weight regain, the treatment might need to be life-long.
This opinion is supported by pharmaceutical companies, who say that the findings "emphasize the persistent character of excess weight," comparing it to managing conditions like diabetes.
User Experiences
Individuals who have stopped the medication explain a intense return of hunger.
"I experienced a trigger that goes on and I was suddenly extremely hungry," described an individual.
This difficulty is compounded if individuals have not developed lasting dietary or behavioural modifications during therapy.
Significant Adoption
Survey data indicate that a significant number of adults in the UK have used these injections in the past year, with demand continuing to grow.
- Use is more common among women than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Finally, clinicians stress that while these medications are effective tools for shedding pounds, they are not a permanent cure and maintained weight loss relies on integrated lifestyle changes.
